Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: The MMKD Study

Kidney International

Volumn 75, Issue 4, 2009, Pages 408-414

  Dieplinger, Benjamin ^a   Mueller, Thomas ^a   Kollerits, Barbara ^b   Struck, Joachim ^c   Ritz, Eberhard ^d   Von Eckardstein, Arnold ^e   Haltmayer, Meinhard ^a   Kronenberg, Florian ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c BRAHMS AG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adrenomedullin; Kidney disease; Natriuretic peptides; Progression of chronic renal failure

Indexed keywords

ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; CREATININE; EPITOPE; HORMONE PRECURSOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA;

EID: 58349093197     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.560     Document Type: Article

References (24)

1. Eknoyan G, Lameire N, Barsoum R et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-1314.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1-S266.
3. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 161-165.
4. Clase CM, Garg AX, Kiberd BA. Classifying kidney problems: can we avoid framing risks as diseases? BMJ 2004; 329: 912-915.
5. Spanaus KS, Kronenberg F, Ritz E et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 2007; 53: 1264-1272.
6. Vesely DL. Atrial natriuretic peptides in pathophysiological diseases. Cardiovasc Res 2001; 51: 647-658.
7. Bunton DC, Petrie MC, Hillier C et al. The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 2004; 103: 179-201.
8. Lerman A, Gibbons RJ, Rodeheffer RJ et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-1109.
9. Jougasaki M, Wei CM, McKinley LJ et al. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995; 92: 286-289.
10. Winters CJ, Sallman AL, Meadows J et al. Two new hormones: prohormone atrial natriuretic peptides 1-30 and 31-67 circulate in man. Biochem Biophys Res Commun 1988; 150: 231-236.
11. Ishimitsu T, Nishikimi T, Saito Y et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94: 2158-2161.
12. Morgenthaler NG, Struck J, Thomas B et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-236.
13. Morgenthaler NG, Struck J, Alonso C et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51: 1823-1829.
14. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140-2144.
15. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol 2003; 285: 167-177.
16. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem 2007; 14: 1689-1699.
17. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptide) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000; 46: 1529-1534.
18. Ala-Kopsala M, Magga J, Peuhkurinen K et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004; 50: 1576-1588.
19. Meeran K, O'Shea D, Upton PD et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 1997; 82: 95-100.
20. Pio R, Martinez A, Unsworth EJ et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001; 276: 12292-12300.
21. Lewis LK, Smith MW, Yandle TG et al. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem 1998; 44: 571-577.
22. Kronenberg F, Kuen E, Ritz E et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-115.
23. Boes E, Fliser D, Ritz E et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2006; 17: 528-536.
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.